Goldman Sachs recently hosted the "Healthcare CEOs Unscripted" conference, and our health care analyst Max Macaluso was particularly interested in the interview with Merck's (MRK -1.75%) CEO, Kenneth Frazier. Max discusses the three takeaways he thought were most important from the talk -- including Merck's business strategy compared to the high profile spinouts recently engineered by Abbott (ABT 0.18%) and Pfizer (PFE 0.30%) -- and also offers his 2013 outlook for Merck.